Reference
1. Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP, Italian
Immunopathology Group ISoN. The Italian experience of the national
registry of renal biopsies. Kidney Int .
2004;66(3):890-4.DOI:10.1111/j.1523-1755.2004.00831.x.2. Hogan J,
Radhakrishnan J. The treatment of minimal change disease in adults.J Am Soc Nephrol . 2013;24(5):702-11.DOI:10.1681/ASN.2012070734.3.
Korbet SM, Whittier WL. Management of Adult Minimal Change Disease.Clin J Am Soc Nephrol .
2019;14(6):911-3.DOI:10.2215/CJN.01920219.4. Matsumoto H, Nakao T, Okada
T, Nagaoka Y, Takeguchi F, Tomaru R, et al. Favorable outcome of
low-dose cyclosporine after pulse methylprednisolone in Japanese adult
minimal-change nephrotic syndrome. Intern Med .
2004;43(8):668-73.DOI:10.2169/internalmedicine.43.668.5. Remy P, Audard
V, Natella PA, Pelle G, Dussol B, Leray-Moragues H, et al. An open-label
randomized controlled trial of low-dose corticosteroid plus
enteric-coated mycophenolate sodium versus standard corticosteroid
treatment for minimal change nephrotic syndrome in adults (MSN Study).Kidney Int . 2018;94(6):1217-26.DOI:10.1016/j.kint.2018.07.021.6.
Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H,
et al. Randomized, Controlled Trial of Tacrolimus and Prednisolone
Monotherapy for Adults with De Novo Minimal Change Disease: A
Multicenter, Randomized, Controlled Trial. Clin J Am Soc Nephrol .
2020;15(2):209-18.DOI:10.2215/CJN.06180519.7. Hofstra JM, Deegens JK,
Wetzels JF. Rituximab: effective treatment for severe steroid-dependent
minimal change nephrotic syndrome? Nephrol Dial Transplant .
2007;22(7):2100-2.DOI:10.1093/ndt/gfm128.8. Lin L, Wang W, Wu Y, Xie J,
Li X, Pan X, et al. Consolidation Treatment and Long-Term Prognosis of
Rituximab in Minimal Change Disease and Focal Segmental Glomerular
Sclerosis. Drug Des Devel Ther .
2021;15:1945-53.DOI:10.2147/DDDT.S302257.9. Heybeli C, Erickson SB,
Fervenza FC, Hogan MC, Zand L, Leung N. Comparison of treatment options
in adults with frequently relapsing or steroid-dependent minimal change
disease. Nephrol Dial Transplant .
2021;36(10):1821-7.DOI:10.1093/ndt/gfaa133.10. Guan N, Zhang M, Zhang M,
Chen R, Xie Q, Hao CM. Rituximab as Initial Therapy in Adult Patients
With Minimal Change Disease. Kidney Int Rep .
2023;8(5):1102-4.DOI:10.1016/j.ekir.2023.02.1070.11. Fenoglio R,
Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, et al.
Rituximab as a front-line therapy for adult-onset minimal change disease
with nephrotic syndrome. Oncotarget .
2018;9(48):28799-804.DOI:10.18632/oncotarget.25612.12. Jamin A,
Berthelot L, Couderc A, Chemouny JM, Boedec E, Dehoux L, et al.
Autoantibodies against podocytic UCHL1 are associated with idiopathic
nephrotic syndrome relapses and induce proteinuria in mice. J
Autoimmun . 2018;89:149-61.DOI:10.1016/j.jaut.2017.12.014.13. Watts AJB,
Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al. Discovery
of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a
Novel Autoimmune Etiology. J Am Soc Nephrol .
2022;33(1):238-52.DOI:10.1681/ASN.2021060794.14. Kim AH, Chung JJ,
Akilesh S, Koziell A, Jain S, Hodgin JB, et al. B cell-derived IL-4 acts
on podocytes to induce proteinuria and foot process effacement.JCI Insight . 2017;2(21).DOI:10.1172/jci.insight.81836.15.
Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, et
al. NEPHRUTIX: A randomized, double-blind, placebo vs
Rituximab-controlled trial assessing T-cell subset changes in Minimal
Change Nephrotic Syndrome. J Autoimmun .
2018;88:91-102.DOI:10.1016/j.jaut.2017.10.006.16. Colucci M, Carsetti R,
Cascioli S, Casiraghi F, Perna A, Rava L, et al. B Cell Reconstitution
after Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am
Soc Nephrol . 2016;27(6):1811-22.DOI:10.1681/ASN.2015050523.17. Iwabuchi
Y, Moriyama T, Itabashi M, Takei T, Nitta K. Rituximab as a Therapeutic
Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in
Adults. Contrib Nephrol . 2018;195:12-9.DOI:10.1159/000486930.18.
Basu B, Angeletti A, Islam B, Ghiggeri GM. New and Old Anti-CD20
Monoclonal Antibodies for Nephrotic Syndrome. Where We Are? Front
Immunol . 2022;13:805697.DOI:10.3389/fimmu.2022.805697.19. Sethi S,
Kumar S, Lim K, Jordan SC. Obinutuzumab is Effective for the Treatment
of Refractory Membranous Nephropathy. Kidney Int Rep .
2020;5(9):1515-8.DOI:10.1016/j.ekir.2020.06.030.20. Marinov AD, Wang H,
Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, et al. The Type
II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than
Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus
Model. Arthritis Rheumatol .
2021;73(5):826-36.DOI:10.1002/art.41608.21. Sato M, Kamei K, Ogura M,
Ishikura K, Ito S. Relapse of nephrotic syndrome during post-rituximab
peripheral blood B-lymphocyte depletion. Clin Exp Nephrol .
2018;22(1):110-6.DOI:10.1007/s10157-017-1415-8.22. Pietro Ravani MC,
Maurizio Bruschi, Marina Vivarelli, Michela Cioni, Armando DiDonato,
et al. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children
with Nephrotic Syndrome: A Superiority Randomized Trial. J Am Soc
Nephrol . 2021;32(10):2652-63.DOI:10.1681/ASN.2021040561.23. DaSilva I,
Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J, et al. Rituximab
for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic
Syndrome in Adults: A Retrospective, Multicenter Study in Spain.BioDrugs . 2017;31(3):239-49.DOI:10.1007/s40259-017-0221-x.24.
Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasa M,
et al. Rituximab in steroid-dependent or frequently relapsing idiopathic
nephrotic syndrome. J Am Soc Nephrol .
2014;25(4):850-63.DOI:10.1681/ASN.2013030251.25. Guitard J, Hebral AL,
Fakhouri F, Joly D, Daugas E, Rivalan J, et al. Rituximab for
minimal-change nephrotic syndrome in adulthood: predictive factors for
response, long-term outcomes and tolerance. Nephrol Dial
Transplant . 2014;29(11):2084-91.DOI:10.1093/ndt/gfu209.26. Takei T,
Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al. Effect
of single-dose rituximab on steroid-dependent minimal-change nephrotic
syndrome in adults. Nephrol Dial Transplant .
2013;28(5):1225-32.DOI:10.1093/ndt/gfs515.27. Munyentwali H, Bouachi K,
Audard V, Remy P, Lang P, Mojaat R, et al. Rituximab is an efficient and
safe treatment in adults with steroid-dependent minimal change disease.Kidney Int . 2013;83(3):511-6.DOI:10.1038/ki.2012.444.28.
Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S,
Korkeila M. Rituximab for minimal change disease in adults: long-term
follow-up. Nephrol Dial Transplant .
2014;29(4):851-6.DOI:10.1093/ndt/gft312.29. Bhatia D, Sinha A, Hari P,
Sopory S, Saini S, Puraswani M, et al. Rituximab modulates T- and
B-lymphocyte subsets and urinary CD80 excretion in patients with
steroid-dependent nephrotic syndrome. Pediatr Res .
2018;84(4):520-6.DOI:10.1038/s41390-018-0088-7.30. Fujinaga S, Hirano D,
Mizutani A, Sakuraya K, Yamada A, Sakurai S, et al. Predictors of
relapse and long-term outcome in children with steroid-dependent
nephrotic syndrome after rituximab treatment. Clin Exp Nephrol .
2017;21(4):671-6.DOI:10.1007/s10157-016-1328-y.31. Pendergraft WF, 3rd,
Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, et al.
Long-term maintenance therapy using rituximab-induced continuous B-cell
depletion in patients with ANCA vasculitis. Clin J Am Soc
Nephrol . 2014;9(4):736-44.DOI:10.2215/CJN.07340713.32. Furie RA, Aroca
G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion
with obinutuzumab for the treatment of proliferative lupus nephritis: a
randomised, double-blind, placebo-controlled trial. Ann Rheum
Dis . 2022;81(1):100-7.DOI:10.1136/annrheumdis-2021-220920.